Redeye provides an initial take following SciBase’s Q2 2026 report.
* Volumes pre-announced, sales +1%, EBIT -10% vs. ABGSCe * Lower quarterly gross margin drives lower...
Surgical Science delivered a strong Q2, with sales 6% above our expectations and an EBIT margin of 1...
Redeye comments in EG7’s Q2-results which saw stronger topline than expected while EBITDA was in lin...
InCoax delivered a better-than-expected Q2, with sales and EBITDA ahead of our estimates, supported ...
Xplora's Q2 revenue came in at NOK 422m in a seasonally neutral quarter, -9% lower than consensus.
Despite end-markets remaining mixed and other external headwinds, Alcadon continued on its path of g...
* Expected return to growth pushed out to Q4 * Adj.
Systemair rapporterar Q1 den 27 augusti med väntad tillväxt på 5 procent och fortsatt stark marginal...
Redeye provides a research update following Optomed’s Q2 2026 report.
Gofore reported Q2 EBITA (adj.) somewhat (EUR 0.7m) ahead of our estimate driven by lower-than-expec...
Q2/26 marked the fifth consecutive quarter with sequential earnings growth for Alcadon, slightly abo...
Hamburg-based Readcrest Capital combines a steady UK domiciliary care provider with German real esta...
Q2 sales were SEK 38m (-2% vs FactSet cons, -5% vs SEBe).
* 10% beat on adj EBIT but lower saIes * -16% organic growth (ABGSCe -15%) * No change in outlook, Q...
Redeye comments on Gentoo Media ahead of Q2-results (due 26 August) where we anticipate a stable qua...
* Q2 growth and profitability much better than expected * We remain in the top end of raised guidanc...
* H1'26e adj. EBIT NOK 46m * Two accretive acquisitions * Fair value range of NOK 18-25 H1'26e adj.
Nätapoteket tar andelar på en marknad i strukturell förflyttning.
Redeye reinforces its positive view of Transtema following the deal extension with Telia.